Share on facebook
Share on twitter
Share on pinterest
Share on telegram
Share on whatsapp
Share on email
Experimental Drugs Inhibit Bone Loss Due To Chemotherapy

, a journal of the American Association for Cancer Research.

Related Articles

‘p38MAPK inhibitors and a MK2 inhibitors could block different parts of the same pathway leading to bone loss. So, they could benefit patients taking chemotherapy, who are at high risk of bone loss.’
Read More..

The researchers further found that this process occurs in males and females and is independent of cancer type.

Bone loss can lead to osteoporosis and fractures is a major problem for cancer patients who receive chemotherapy and radiation.

Since the hormone estrogen plays an important role in maintaining bone health, bone loss is especially pronounced among postmenopausal women with breast cancer who are treated using therapies aimed at eliminating estrogen.


Men and children treated for other cancers also experience bone loss, suggesting that eliminating estrogen is not the only trigger leading to bone degeneration.

“Researchers have understood that this bone loss has to be due to more than just hormone loss,” said senior author Sheila A. Stewart, PhD, a professor of cell biology & physiology. “Cancer patients who receive chemotherapy and radiation lose a lot more bone than women with breast can Read More

Leave a Replay

Recent Posts

Recent Posts

Latest Articles


Clippednews goes Social Media